Keio University

Tomohiro Chiba

Kenzo Terashita

Tomo Nishimoto

Canon Kabushiki Kaisha

Luxonus Inc.

Marina Yamada

Sadakazu Aiso

Masaaki Matsuoka

Massaaki Matsuoka

Sadakazu Also

Ikuo Nishimoto

Tomo Nishimoto, Legal Representative

Jin Nakahara

Kenichi Nagae

Norihiro Suzuki

Hiroaki Asou

Yoshiko Kita

Hiroki Kajita

Nobuaki Imanishi

An aspect provides an image processing apparatus processing three-dimensional image data generated based on a photoacoustic wave generated from inside of a subject. The image processing apparatus includes first three-dimensional image acquisition unit for acquiring first three-dimensional image data in which a first region corresponding to a first substance in the subject is extracted from the three-dimensional image data, second three-dimensional image acquisition unit for acquiring second three-dimensional image data in which a second region corresponding to a second substance in the subject is extracted from the three-dimensional image data, first two-dimensional image acquisition unit for acquiring first two-dimensional image data associated with three-dimensional positional information of the first region from the first three-dimensional image data, and second two-dimensional image acquisition unit for acquiring second two-dimensional image data associated with three-dimensional positional information of the second region from the second three-dimensional image data.

Image processing apparatus and image processing method and non-transitory computer-readable medium

It is intended to provide a drug delivery system toward a demyelinating lesion. It is also intended to provide a biochemical marker of a demyelinating lesion. A delivery system for a prophylactic and/or therapeutic agent for a demyelinating disease characterized in that a substance capable of specifically recognizing Contactin is conjugated to an active ingredient of a prophylactic and/or therapeutic agent for a demyelinating disease is provided. Also provided is a method of evaluating and/or differentiating a demyelinating disease, including measuring the expression of Contactin in a body fluid.

Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion

The present invention provides a method for detecting or diagnosing in vitro Alzheimer's disease, or memory and/or cognitive disorders, using a human biological sample and the inactivation of STAT3 protein as an indication, and a method for screening for a therapeutic drug for Alzheimer's disease or memory and/or cognitive disorders, using the activation of STAT3 protein as an indication.

Method for detecting candidate alzheimer's disease drug

One aspect of the present invention is directed to search receptors based on the information of HN signaling pathways in order to find Humanin receptor or Humanin-like polypeptide receptor (HNR), and to reveal a mechanism of promoting or suppressing the intracellular signal transduction for neuroprotecting activity of HN and identify a compound involved in the mechanism. The aspect of the invention is directed to a method for screening of HNR agonist and HNR antagonist, to utilize the screened compound in development of a drug for the treatment of neurodegenerative disease, and to provide an assay system of AD neuronal cell death, and to provide methods for the compulsory expression of HNR gene or knocking-out of intracellular genes.

Humanin receptor or humanin-like polypeptide receptor

The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a neurodegenerative disease, comprising the following polypeptide shown in any of (a) to (c): (a) a polypeptide comprising the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); (b) a polypeptide comprising an amino acid sequence having a deletion, substitution, insertion, and/or addition of one or several amino acids in the amino acid sequence consisting of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death associated with neurodegenerative disease; and (c) a modified polypeptide from the polypeptide (a) or (b), or a pharmaceutically acceptable salt thereof, as an effective ingredient.

Therapeutic agents of colivelin for neurodegenerative diseases

The present invention provides pharmaceutical compositions composing, as an active ingredient, a substance capable of activating the &#x3b3; chain of Fc receptors (FcR&#x3b3;) (provided that the substance is not an immunoglobulin for intravenous injection), and agents for stimulating myelinogenesis. The invention also provides agents for stimulating the differentiation of oligodendroglial precursor cells, agents for activating Fyn tyrosine kinase, and agents for stimulating the expression of myelin basic protein, all comprising a substance capable of activating FcR&#x3b3; as an active ingredient. Further, the invention provides a method of detecting myelinogenetic oligodendroglias or precursor cells thereof which comprises using the expression of FcR&#x3b3; in oligodendroglias or precursor cells thereof as an indicator.

Medicinal compositions containing Fc receptor &#x3b3; chain activator

Growing community of inventors

Tokyo, Japan

Sadakazu Aiso